Trial Profile
A Safety and Efficacy Study of Chimeric Switch Receptor Modified T Cells in Patients With Recurrent or Metastatic Malignant Tumors
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Anti-PD-L1 CSR T cells (Primary)
- Indications Advanced breast cancer; Colorectal cancer; Lung cancer; Lymphoma; Pancreatic cancer; Renal cancer; Tumours
- Focus Adverse reactions
- 25 Oct 2016 New trial record